Hyman Charles D Boosts Stock Position in Abbott Laboratories (NYSE:ABT)

Hyman Charles D raised its position in shares of Abbott Laboratories (NYSE:ABT) by 0.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 44,339 shares of the healthcare product maker’s stock after buying an additional 247 shares during the quarter. Hyman Charles D’s holdings in Abbott Laboratories were worth $4,880,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Signature Resources Capital Management LLC acquired a new stake in Abbott Laboratories in the fourth quarter valued at approximately $29,000. Stuart Chaussee & Associates Inc. grew its stake in Abbott Laboratories by 236.0% during the 4th quarter. Stuart Chaussee & Associates Inc. now owns 336 shares of the healthcare product maker’s stock worth $37,000 after buying an additional 236 shares during the last quarter. Rise Advisors LLC acquired a new position in Abbott Laboratories during the 4th quarter valued at about $37,000. Stonehage Fleming Financial Services Holdings Ltd purchased a new stake in shares of Abbott Laboratories during the third quarter worth about $40,000. Finally, Cornerstone Planning Group LLC raised its position in shares of Abbott Laboratories by 79.4% in the 3rd quarter. Cornerstone Planning Group LLC now owns 454 shares of the healthcare product maker’s stock valued at $44,000 after purchasing an additional 201 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, EVP Andrea F. Wainer sold 12,500 shares of Abbott Laboratories stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the sale, the executive vice president now owns 78,704 shares of the company’s stock, valued at approximately $9,444,480. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, EVP Andrea F. Wainer sold 12,500 shares of the firm’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the completion of the sale, the executive vice president now directly owns 78,704 shares of the company’s stock, valued at approximately $9,444,480. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP John A. Jr. Mccoy sold 472 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $118.50, for a total transaction of $55,932.00. Following the completion of the sale, the vice president now owns 18,760 shares in the company, valued at $2,223,060. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,935 shares of company stock worth $1,670,048. Insiders own 0.47% of the company’s stock.

Abbott Laboratories Price Performance

ABT traded up $0.53 on Tuesday, hitting $106.17. 6,555,967 shares of the company’s stock were exchanged, compared to its average volume of 5,552,894. The stock has a market cap of $184.70 billion, a price-to-earnings ratio of 33.07, a P/E/G ratio of 2.55 and a beta of 0.76. Abbott Laboratories has a fifty-two week low of $89.67 and a fifty-two week high of $121.64. The firm has a 50-day moving average price of $112.00 and a 200-day moving average price of $108.85. The company has a current ratio of 1.60, a quick ratio of 1.11 and a debt-to-equity ratio of 0.32.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, April 17th. The healthcare product maker reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.96 by $0.02. The firm had revenue of $9.96 billion for the quarter, compared to the consensus estimate of $9.88 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.96%. The firm’s revenue was up 2.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.03 earnings per share. As a group, equities analysts anticipate that Abbott Laboratories will post 4.62 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.07%. The ex-dividend date of this dividend is Friday, April 12th. Abbott Laboratories’s dividend payout ratio is currently 68.54%.

Analyst Ratings Changes

A number of brokerages have issued reports on ABT. Raymond James restated a “buy” rating and set a $124.00 price target on shares of Abbott Laboratories in a research note on Wednesday, April 24th. Royal Bank of Canada dropped their target price on Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating on the stock in a research report on Thursday, April 18th. Barclays decreased their price objective on shares of Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating for the company in a research note on Monday, April 22nd. Citigroup increased their price target on Abbott Laboratories from $126.00 to $128.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Finally, Evercore ISI lifted their price target on Abbott Laboratories from $120.00 to $125.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $121.50.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.